Story excerpt provided by Crain’s Cleveland Business.
GenomOncology, a Cleveland, Ohio company that has developed a technology platform to streamline the use of next-generation sequencing data in medical care and research, announced it’s working with Thomas Jefferson University Hospital in Philadelphia to develop an interpretation and reporting system for cancer profiling.
Jefferson expects to launch the system for testing acute myeloid leukemia, or AML, in its molecular pathology laboratory this fall, according to a news release from the company and the hospital.
Click here to read the complete article.
Originally published September 18, 2015.